179 related articles for article (PubMed ID: 34764108)
1. Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory mixed-phenotype blast crisis in chronic myeloid leukaemia.
Ovilla-Martinez R; Weber Sánchez LA; Cota-Rangel X; Baez-Islas PE
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34764108
[TBL] [Abstract][Full Text] [Related]
2. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
Qing X; Qing A; Ji P; French SW; Mason H
Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
[TBL] [Abstract][Full Text] [Related]
3. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
[TBL] [Abstract][Full Text] [Related]
4. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
5. Bilineal Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Literature Review.
Gao X; Li J; Wang L; Lin J; Jin H; Xu Y; Wang N; Zhao Y; Liu D; Yu L; Wang Q
Am J Case Rep; 2016 Oct; 17():793-798. PubMed ID: 27784881
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
Ghez D; Micol JB; Pasquier F; Auger N; Saada V; Spentchian M; Ianotto JC; Bourhis JH; Bennaceur-Griscelli A; Terré C; Castaigne S; Rigaudeau S; Rousselot P; de Botton S
Eur J Cancer; 2013 Nov; 49(17):3666-70. PubMed ID: 23968731
[TBL] [Abstract][Full Text] [Related]
7. Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase.
Patel SA; Bledsoe JR; Higgins AW; Hutchinson L; Gerber JM
JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34409243
[No Abstract] [Full Text] [Related]
8. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E; Short NJ; Jain N; Huang X; Montalban-Bravo G; Banerjee P; Rezvani K; Jiang X; Kim KH; Kanagal-Shamanna R; Khoury JD; Patel K; Kadia TM; Daver N; Chien K; Alvarado Y; Garcia-Manero G; Issa GC; Haddad FG; Kwari M; Thankachan J; Delumpa R; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
Lancet Haematol; 2023 Jan; 10(1):e24-e34. PubMed ID: 36402146
[TBL] [Abstract][Full Text] [Related]
11. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
Liu YL; Wang XN; Liu HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):629-33. PubMed ID: 24989266
[TBL] [Abstract][Full Text] [Related]
12. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
13. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
15. Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia.
Malik ST; Tucker J; Rohatiner AZ; Brace W; Lister TA
Hematol Oncol; 1989; 7(6):423-7. PubMed ID: 2807180
[TBL] [Abstract][Full Text] [Related]
16. Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
Copland M
Br J Haematol; 2022 Dec; 199(5):665-678. PubMed ID: 35866251
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
19. Extramedullary Blast Crisis of Chronic Myelogenous Leukemia With a Skin Lesion: A Case Report and Literature Review.
Qi J; Zhang F; Liu Y; Yao J; Xu Y; He H
Am J Dermatopathol; 2021 Jun; 43(6):450-453. PubMed ID: 33481378
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.
Senapati J; Jabbour E; Kantarjian H; Short NJ
Leukemia; 2023 Jan; 37(1):5-17. PubMed ID: 36309558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
